Sophie Lucas

This inventor holds 21 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Ludwig Institute for Cancer Research Limited, Universitè Catholique De Louvain, Argenx Bvba. Active years: 1998-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sophie Lucas. Retrieved from https://idiyas.com/inventor/sophie-lucas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 3)

% Patents Active = 85.7

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 4.4

ph-index = 4

Forward Citations = 111(Granted Patents)

Location History:

Brussels, BE (1998 - 2011)
Tervuren, BE (2018 - 2020)
Duisburg, BE (2019 - 2022)

Company Filing History:

13 out of 530

Ludwig Institute for Cancer Research Limited

patents

6 out of 100

Universitè Catholique De Louvain

National Institute of Health and Medical Research

patents

5. 1 out of 2

Ludwig Institute for Cancer

patents

6. 1 out of 1

Université Catholique De Louvian

patent

where one patent can have more than one assignee

Years Active: 1998-2022

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11230603 - Anti-GARP protein (2022-01-25),

2. 10875914 - Nucleic acids encoding GARP-TGF-beta 1 antibodies (2020-12-29),

3. 10822424 - Method of screening for anti-GARP antibodies (2020-11-03),

4. 10793627 - GARP-TGF-β 1 IGG antibodies (2020-10-06),

5. 10604579 - Antibody against a complex between human GARP and latent TGF-β (2020-03-31),

6. 10479829 - GARP-TGF-beta 1 antibodies (2019-11-19),

7. 10000572 - Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody (2018-06-19),

8. 7998483 - Lage-1 tumor associated nucleic acids (2011-08-16),

9. 7563870 - LAGE-1 tumor associated nucleic acids (2009-07-21),

10. 7022819 - Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof (2006-04-04),

11. 6794131 - Lage-1 tumor associated nucleic acids (2004-09-21),

12. 6680191 - Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof (2004-01-20),

13. 6475783 - Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof (2002-11-05),

14. 6271019 - Leukemia associated genes (2001-08-07),

15. 6130052 - Leukemia associated genes (2000-10-10),

Title: Sophie Lucas: Pioneering Inventor from Duisburg

Introduction: Sophie Lucas is a trailblazing inventor hailing from Duisburg, Belgium. She is renowned for her innovative spirit and groundbreaking contributions to the field of technology.

Latest Patents: Sophie Lucas holds several patents in the areas of renewable energy technologies and sustainable materials. Her most recent patent involves a revolutionary method for harnessing solar power in urban environments.

Career Highlights: With a career spanning over two decades, Sophie Lucas has worked for leading tech companies, spearheading research and development projects that have pushed the boundaries of innovation. Her expertise in renewable energy solutions has garnered international recognition.

Collaborations: Throughout her career, Sophie Lucas has collaborated with top research institutions and universities to further her inventions. Her partnerships have led to the development of cutting-edge technologies that are shaping the future of sustainable energy.

Conclusion: Sophie Lucas's dedication to innovation and sustainability has solidified her reputation as a visionary inventor. Her work continues to inspire the next generation of inventors and pave the way for a more sustainable future.

Profile summary based on public USPTO records.